Alpha-1 adrenergic receptor and Alpha-2A adrenergic receptor (α1-adrenergic receptor, α2A-adrenergic receptor)

Alpha-1 adrenergic receptor and Alpha-2A adrenergic receptor are members of the G protein-coupled receptor (GPCR) superfamily that bind endogenous catecholamines (norepinephrine and epinephrine), playing critical roles in the sympathetic nervous system’s regulation of vascular tone, neurotransmitter release, and autonomic homeostasis. The α1 receptor (with main subtypes α1A, α1B, α1D) is predominantly expressed on vascular smooth muscle and mediates contraction, resulting in vasoconstriction and increased blood pressure; it also regulates other functions like glycogenolysis and certain secretions[1][3][4][5]. The α2A subtype, one of several α2 adrenergic receptor subtypes, is primarily expressed presynaptically on nerve terminals, where it inhibits further norepinephrine release (negative feedback), and centrally in the brainstem, where its activation reduces sympathetic outflow, lowers blood pressure, and produces sedation and analgesia[1][2][4][7]. Both receptors are important drug targets: α1 antagonists are used for hypertension and benign prostatic hyperplasia, α2A agonists for hypertension, sedation, ADHD, and pain management. Their side effect profiles and therapeutic applications are determined by their location and the physiological effects of their activation or inhibition.

Other names

Alpha-1 adrenoceptorα1-adrenoceptorAlpha-2A adrenoceptorα2A-adrenoceptorAlpha-adrenergic receptor (generic for the overall family—less specific)Alpha-adrenergic receptor subtype A, Alpha-2A (for Alpha-2A only)

Agonism at α1: induces smooth muscle contraction and vasoconstriction via Gq-mediated phospholipase C activation and IP3/DAG signaling[3][5]. Antagonism at α1: relaxes vascular smooth muscle, lowers blood pressure, treats urinary outflow obstruction[7]. Agonism at α2A: inhibits norepinephrine release (auto-receptor function), decreases sympathetic outflow (centrally), lowers blood pressure, provides analgesia and sedation (centrally acting agents)[1][7]. Antagonism at α2A: increases norepinephrine release; not widely therapeutic.